Factors Associated With Immune Checkpoint Inhibitor–Related Myocarditis
Cet article analyse les facteurs associés au risque de myocardite chez des patients atteints d'un cancer traité par inhibiteurs de points de contrôle immunitaire
Immune-related adverse events (irAE) can develop in patients treated with immune checkpoint inhibitors (ICIs). For example, ICI treatment can increase the risk of myocarditis as a lethal irAE,1 with a mortality rate up to 50%.2 However, the frequency of ICI-related myocarditis is low, and thus the detailed pathogenic mechanisms and risk factors remain unknown. General myocarditis and ICI-related myocarditis have distinct manifestations, suggesting different risk factors; however, the differences of risk factors in these 2 types are unclear
JAMA Oncology 2019